242 related articles for article (PubMed ID: 25625848)
1. Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma.
Hallberg AR; Vorrink SU; Hudachek DR; Cramer-Morales K; Milhem MM; Cornell RA; Domann FE
Epigenetics; 2014 Dec; 9(12):1641-7. PubMed ID: 25625848
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
4. Silencing of the thrombomodulin gene in human malignant melanoma.
Furuta J; Kaneda A; Umebayashi Y; Otsuka F; Sugimura T; Ushijima T
Melanoma Res; 2005 Feb; 15(1):15-20. PubMed ID: 15714116
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
[TBL] [Abstract][Full Text] [Related]
6. TFAP2 paralogs regulate melanocyte differentiation in parallel with MITF.
Seberg HE; Van Otterloo E; Loftus SK; Liu H; Bonde G; Sompallae R; Gildea DE; Santana JF; Manak JR; Pavan WJ; Williams T; Cornell RA
PLoS Genet; 2017 Mar; 13(3):e1006636. PubMed ID: 28249010
[TBL] [Abstract][Full Text] [Related]
7. Synergistic silencing by promoter methylation and reduced AP-2α transactivation of the proapoptotic HRK gene confers apoptosis resistance and enhanced tumor growth.
Xu M; Chen X; Chen N; Nie L; Li X; Li Q; Zeng H; Zhou Q
Am J Pathol; 2013 Jan; 182(1):84-95. PubMed ID: 23159945
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.
Gao L; Smit MA; van den Oord JJ; Goeman JJ; Verdegaal EM; van der Burg SH; Stas M; Beck S; Gruis NA; Tensen CP; Willemze R; Peeper DS; van Doorn R
Pigment Cell Melanoma Res; 2013 Jul; 26(4):542-54. PubMed ID: 23590314
[TBL] [Abstract][Full Text] [Related]
9. Silencing of metallothionein 1A gene in melanoma.
Nobeyama Y; Nakagawa H
J Dermatol Sci; 2017 Nov; 88(2):232-237. PubMed ID: 28764861
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma.
Venza M; Visalli M; Biondo C; Lentini M; Catalano T; Teti D; Venza I
Biochim Biophys Acta; 2015 Mar; 1849(3):247-56. PubMed ID: 25497382
[TBL] [Abstract][Full Text] [Related]
11. Aberrant p27Kip1 promoter methylation in malignant melanoma.
Worm J; Bartkova J; Kirkin AF; Straten P; Zeuthen J; Bartek J; Guldberg P
Oncogene; 2000 Oct; 19(44):5111-5. PubMed ID: 11042700
[TBL] [Abstract][Full Text] [Related]
12. Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation.
Stengel S; Fiebig U; Kurth R; Denner J
Genes Chromosomes Cancer; 2010 May; 49(5):401-11. PubMed ID: 20095041
[TBL] [Abstract][Full Text] [Related]
13. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.
Furuta J; Nobeyama Y; Umebayashi Y; Otsuka F; Kikuchi K; Ushijima T
Cancer Res; 2006 Jun; 66(12):6080-6. PubMed ID: 16778180
[TBL] [Abstract][Full Text] [Related]
14. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.
Wang H; Lee S; Nigro CL; Lattanzio L; Merlano M; Monteverde M; Matin R; Purdie K; Mladkova N; Bergamaschi D; Harwood C; Syed N; Szlosarek P; Briasoulis E; McHugh A; Thompson A; Evans A; Leigh I; Fleming C; Inman GJ; Hatzimichael E; Proby C; Crook T
Br J Cancer; 2012 Apr; 106(8):1446-52. PubMed ID: 22454080
[TBL] [Abstract][Full Text] [Related]
15. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.
Nobeyama Y; Okochi-Takada E; Furuta J; Miyagi Y; Kikuchi K; Yamamoto A; Nakanishi Y; Nakagawa H; Ushijima T
Int J Cancer; 2007 Jul; 121(2):301-7. PubMed ID: 17372906
[TBL] [Abstract][Full Text] [Related]
16. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation status of multiple genes in uveal melanoma.
Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
[TBL] [Abstract][Full Text] [Related]
18. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.
Shen L; Kondo Y; Ahmed S; Boumber Y; Konishi K; Guo Y; Chen X; Vilaythong JN; Issa JP
Cancer Res; 2007 Dec; 67(23):11335-43. PubMed ID: 18056460
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation profiling of 30 genes in human malignant melanoma.
Furuta J; Umebayashi Y; Miyamoto K; Kikuchi K; Otsuka F; Sugimura T; Ushijima T
Cancer Sci; 2004 Dec; 95(12):962-8. PubMed ID: 15596045
[TBL] [Abstract][Full Text] [Related]
20. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
